Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY
We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x...
170 Views
Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26
Growth was led by CVS, anti-diabetes, pain, VMN, and oncology segments, while growth in anti-infective and respiratory was below IPM growth
149 Views
Pharma and Healthcare (Q4FY26E Results Preview): Steady revenue growth, margins pressure visible
Our assumptions are: (1) Pharma coverage will see 10% YoY sales growth driven by 15% YoY increase in the India business (ex-Torrent + JB growth at...
155 Views
Pharmaceuticals: US tariffs on branded drugs, generics exempted
We believe the key motive behind tariffs is to push the innovator company toward MFN or investment in plants/R&D to bring down drug prices.
163 Views
Pharmaceuticals: IPM: steady 11% growth in Jan-26
As per IQVIA, IPM recorded strong growth for Jan-26 at 11% YoY (vs 15% in Dec-25), units grew by 1.1% YoY (4.4%% in Dec-25). Growth was led by CVS,...
171 Views